Navigation Links
Lotus Pharmaceuticals' Laevo-Bambuterol Received SFDA Approval to Commence Clinical Trials
Date:4/29/2010

BEIJING, April 29 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a growing developer, manufacturer and seller of medicine and drugs in the People's Republic of China (the "PRC") today reported that its innovative asthma drug Laevo-Bambuterol has received approval from China's State Food & Drug Administration's (SFDA) to commence clinical trials (No.2010L01309 and 2010L01399).

R-Bambuterol(R) Hydrochloride Tablets ("Laevo-Bambuterol") is categorized as a Class 1 new drug. Its preclinical studies show that it is more effective and have lower toxicity than Bambuterol, a popular asthma drug currently on the market.

The Company is communicating with experts from the SFDA's Drug Review and Evaluation Center on the designs for clinical trials and expects the new product to launch in 2013-2014.

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intent," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may," or words or expressions of similar meaning. Such statements are not guarantees of future performance and could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including, but not limited to, changes from anticipated levels of s
'/>"/>

SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
2. Lotus Pharmaceuticals, Inc.s New Drug Laevo-Bambutero Begins Evaluation for Clinical Trials
3. Lotus Pharmaceuticals, Inc. Reports Third-Quarter 2009 Results
4. Lotus Pharmaceuticals, Inc. to Exhibit at the 62nd PHARMCHINA
5. Lotus Pharmaceuticals, Inc. Strengthens Beijing Presence with Direct Sales to Drug Stores
6. Lotus Pharmaceuticals Reports Groundbreaking Ceremony
7. Lotus Pharmaceuticals to Exhibit at the 63rd PHARMCHINA
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Conn. , Sept. 1, 2015  Results from ... AD™ study demonstrate that 5g of idarucizumab enabled ... situations involving patients treated with dabigatran (Pradaxa ® ... of the anticoagulant effect of dabigatran enabled patients ... a median time of 1.7 hours between administration ...
(Date:9/1/2015)... , Belgium , Sept. 1, 2015 /PRNewswire/ ... sciences company focused on developing blood-based diagnostic tests for a ... that its Chief Executive Officer, Cameron Reynolds , is ... Healthcare Conference, which is being held September 9-10, 2015 in ... meetings all day on September 10. Wells ...
(Date:9/1/2015)... 1, 2015   Ivenix Inc. , a ... system, closed on a $42M round of equity ... Cardinal Partners, CICA, Inc., Easterly Capital, Fidelity Biosciences, ... round. This financing will support the company,s efforts ... Partners LLC acted as the exclusive placement agent ...
Breaking Medicine Technology:New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 2New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 3New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 4New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 5New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 6New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 7New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 8New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 9VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015 2VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015 3VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015 4Ivenix Inc. Secures $42 Million in Funding 2Ivenix Inc. Secures $42 Million in Funding 3
... 2011 Boston Scientific Corporation (NYSE: BSX ) ... at the 32nd Annual Scientific Sessions of the Heart Rhythm ... scheduled clinical presentations will provide new insights for physicians who ... fibrillation and heart failure. Schedule of Events ...
... Aoxing Pharmaceutical (NYSE Amex: AXN ... on research, development, manufacturing and distribution of narcotic ... in China, Hebei Aoxing Pharmaceutical Group Company, has ... Property Office of The People,s Republic of China ...
Cached Medicine Technology:Boston Scientific Announces Its Schedule for Heart Rhythm Society Scientific Sessions 2Boston Scientific Announces Its Schedule for Heart Rhythm Society Scientific Sessions 3Boston Scientific Announces Its Schedule for Heart Rhythm Society Scientific Sessions 4Aoxing Pharmaceutical Company Announces Issuance of Chinese Patent for Naloxone Sublingual Film 2Aoxing Pharmaceutical Company Announces Issuance of Chinese Patent for Naloxone Sublingual Film 3
(Date:9/1/2015)... ... 2015 , ... Celebrity hairstylist and Beauty Gives Back Art Team member Ted ... on Thursday, Oct. 1, at the La Valencia Hotel. The presentation, on the eve ... fashion and professional hair, makeup and nail design. , The evening of beauty ...
(Date:9/1/2015)... ... ... Philanthropic giving in the U.S. has been stuck at 2% GDP since ... released today by Camber Collective, goes to the root of this problem and provides ... in new philanthropic giving and shift $25B that’s already being donated, according to the ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... colleges and universities across the country in stemming sexual assaults on their campuses. ... Collaborative (ARC3), a consortium of sexual assault researchers and student affairs professionals responding ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... members of the American Society for Dermatologic Surgery, according to a new survey ... ASDS Consumer Survey on Cosmetic Dermatologic Procedures – which reflects views on cosmetic ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... Splashtop Business for Remote Support , a solution optimized for MSPs and ... with the escalating renewal prices and inadequate customer services of existing remote support ...
Breaking Medicine News(10 mins):Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 2Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 3Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 2Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 3Health News:Georgia State, Partners Introduce Climate Survey to Aid in Preventing Campus Sexual Assaults 2Health News:Survey: Consumers Prefer ASDS Members 2Health News:Survey: Consumers Prefer ASDS Members 3Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 2Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 3Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 4
... disease, treatment response , THURSDAY, Feb. 18 (HealthDay News) -- ... a cancer, and then use that fingerprint to track the ... "[This technique] will allow us to measure the amount of ... is identified by biopsy," said study co-author Dr. Luis Diaz, ...
... , , PITTSBURGH , Feb. 18 ... use of a drug that illuminates brain tumor cells to ... to surgically excise tumors and improve patient survival. , AGH ... approved by the U.S. Food and Drug Administration to investigate ...
... University of Florida aquatic animal health experts say dolphins ... cervical cancer in people. "We discovered that dolphins ... be linked with cervical cancer in women," said Hendrik ... at UF,s College of Veterinary Medicine today (Feb. 18) ...
... ... Health of Illinois has been designated as a Health Information Technology “Regional Extension Center” ... primary care practices, federally qualified health centers, and critical access hospitals with the selection ... ...
... ... to land an NFL Draft pick would have to find a personal ... specialists to help them compete with the best athletes in the world. ... Athletes, Performance has offered an NFL Combine preparation program, and this year ...
... It is not unusual to hear people blame their metabolism after ... that shapes how our bodies turn food into energy -- can ... into your favorite jeans. In fact, differences in metabolic ... though the mechanism behind it is unclear. Now new research from ...
Cached Medicine News:Health News:Scientists Spot Genetic 'Fingerprints' of Individual Cancers 2Health News:Scientists Spot Genetic 'Fingerprints' of Individual Cancers 3Health News:Pittsburgh Neurosurgeons Explore Use of Drug that Illuminates Brain Tumor Cells To Guide Surgery 2Health News:Pittsburgh Neurosurgeons Explore Use of Drug that Illuminates Brain Tumor Cells To Guide Surgery 3Health News:Dolphins could be ideal model to study human cervical cancer, UF veterinarians say 2Health News:Electronic Health Record Assistance for Central Illinois Medical Practices 2Health News:Electronic Health Record Assistance for Central Illinois Medical Practices 3Health News:Electronic Health Record Assistance for Central Illinois Medical Practices 4Health News:Small Time Company Rolls into the Big League: Trigger Point Performance Therapy Selected to Attend Athletes' Performance NFL Combine Preparation Program 2Health News:Small Time Company Rolls into the Big League: Trigger Point Performance Therapy Selected to Attend Athletes' Performance NFL Combine Preparation Program 3Health News:Chemical tags likely to affect metabolism, cancer development 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: